J Cui1, B Ang1, W Haufe2, C Hernandez1, E C Verna3, C B Sirlin2, R Loomba1,4,5. 1. NAFLD Translational Research Unit, Department of Medicine, University of California at San Diego, La Jolla, CA, USA. 2. Liver Imaging Group, Department of Radiology, University of California at San Diego, La Jolla, CA, USA. 3. Center for Liver Disease and Transplantation, Division of Digestive and Liver Diseases, Columbia University College of Physicians and Surgeons, New York, NY, USA. 4. Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, CA, USA. 5. Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, CA, USA.
Abstract
BACKGROUND: Two-dimensional magnetic resonance elastography (2D-MRE) is an advanced magnetic resonance method with high diagnostic accuracy for predicting advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) patients. However, no prospective, head-to-head comparisons between 2D-MRE and clinical prediction rules (CPRs) have been performed in patients with biopsy-proven NAFLD. AIM: To compare the diagnostic utility of 2D-MRE against that of eight CPRs (AST:ALT ratio, APRI, BARD, FIB-4, NAFLD Fibrosis Score, Bonacini cirrhosis discriminant score, Lok Index and NASH CRN model) for predicting advanced fibrosis in a prospective cohort with paired liver biopsy as the gold standard. METHODS: This is a cross-sectional analysis of a prospective study of 102 patients (58.8% women) with biopsy-proven NAFLD, 2D-MRE and clinical research assessment within 90 days of biopsy. Receiver operating characteristic (ROC) analysis was performed to assess the performance of 2D-MRE and CPRs for predicting advanced fibrosis. RESULTS: The mean (±s.d.) age and BMI were 51.3 (±14.0) years and 31.7 (±5.5) kg/m(2) respectively. 48, 26, 9, 13 and 6 patients had stage 0, 1, 2, 3 and 4 fibrosis respectively. The area under ROC curve (AUROC) was 0.957 for 2D-MRE and between 0.796 and 0.861 for the CPRs. FIB-4 was the best-performing CPR at predicting advanced fibrosis with AUROC of 0.861. In head-to-head comparisons using the DeLong test, 2D-MRE had significantly better AUROC (P < 0.05) than each CPR for predicting advanced fibrosis. CONCLUSION: Compared to clinical prediction rules, 2D-MRE provides significantly higher accuracy for the diagnosis of advanced fibrosis in NAFLD patients.
BACKGROUND: Two-dimensional magnetic resonance elastography (2D-MRE) is an advanced magnetic resonance method with high diagnostic accuracy for predicting advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) patients. However, no prospective, head-to-head comparisons between 2D-MRE and clinical prediction rules (CPRs) have been performed in patients with biopsy-proven NAFLD. AIM: To compare the diagnostic utility of 2D-MRE against that of eight CPRs (AST:ALT ratio, APRI, BARD, FIB-4, NAFLD Fibrosis Score, Bonacini cirrhosis discriminant score, Lok Index and NASH CRN model) for predicting advanced fibrosis in a prospective cohort with paired liver biopsy as the gold standard. METHODS: This is a cross-sectional analysis of a prospective study of 102 patients (58.8% women) with biopsy-proven NAFLD, 2D-MRE and clinical research assessment within 90 days of biopsy. Receiver operating characteristic (ROC) analysis was performed to assess the performance of 2D-MRE and CPRs for predicting advanced fibrosis. RESULTS: The mean (±s.d.) age and BMI were 51.3 (±14.0) years and 31.7 (±5.5) kg/m(2) respectively. 48, 26, 9, 13 and 6 patients had stage 0, 1, 2, 3 and 4 fibrosis respectively. The area under ROC curve (AUROC) was 0.957 for 2D-MRE and between 0.796 and 0.861 for the CPRs. FIB-4 was the best-performing CPR at predicting advanced fibrosis with AUROC of 0.861. In head-to-head comparisons using the DeLong test, 2D-MRE had significantly better AUROC (P < 0.05) than each CPR for predicting advanced fibrosis. CONCLUSION: Compared to clinical prediction rules, 2D-MRE provides significantly higher accuracy for the diagnosis of advanced fibrosis in NAFLD patients.
Authors: Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal Journal: Hepatology Date: 2012-06 Impact factor: 17.425
Authors: Leon A Adams; Jacob George; Elisabetta Bugianesi; Enrico Rossi; W Bastiaan De Boer; David van der Poorten; Helena L I Ching; Max Bulsara; Gary P Jeffrey Journal: J Gastroenterol Hepatol Date: 2011-10 Impact factor: 4.029
Authors: Z Permutt; T-A Le; M R Peterson; E Seki; D A Brenner; C Sirlin; R Loomba Journal: Aliment Pharmacol Ther Date: 2012-05-03 Impact factor: 8.171
Authors: Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison Journal: Gastroenterology Date: 2010-09-19 Impact factor: 22.682
Authors: Jun Chen; Jayant A Talwalkar; Meng Yin; Kevin J Glaser; Schuyler O Sanderson; Richard L Ehman Journal: Radiology Date: 2011-04-01 Impact factor: 11.105
Authors: Jacob A Udell; Charlie S Wang; Jill Tinmouth; J Mark FitzGerald; Najib T Ayas; David L Simel; Michael Schulzer; Edwin Mak; Eric M Yoshida Journal: JAMA Date: 2012-02-22 Impact factor: 56.272
Authors: Thuy-Anh Le; Joshua Chen; Christopher Changchien; Michael R Peterson; Yuko Kono; Heather Patton; Benjamin L Cohen; David Brenner; Claude Sirlin; Rohit Loomba Journal: Hepatology Date: 2012-07-02 Impact factor: 17.425
Authors: Rachel M Williamson; Jackie F Price; Stephen Glancy; Elisa Perry; Lisa D Nee; Peter C Hayes; Brian M Frier; Liesbeth A F Van Look; Geoffrey I Johnston; Rebecca M Reynolds; Mark W J Strachan Journal: Diabetes Care Date: 2011-04-08 Impact factor: 19.112
Authors: Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner Journal: Gastroenterology Date: 2015-08-20 Impact factor: 22.682
Authors: M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal Journal: Aliment Pharmacol Ther Date: 2016-01-19 Impact factor: 8.171
Authors: Mohammad S Siddiqui; Raj Vuppalanchi; Mark L Van Natta; Erin Hallinan; Kris V Kowdley; Manal Abdelmalek; Brent A Neuschwander-Tetri; Rohit Loomba; Srinivasan Dasarathy; Danielle Brandman; Edward Doo; James A Tonascia; David E Kleiner; Naga Chalasani; Arun J Sanyal Journal: Clin Gastroenterol Hepatol Date: 2018-04-26 Impact factor: 11.382
Authors: Y A Patel; E J Gifford; L M Glass; R McNeil; M J Turner; B Han; D Provenzale; S S Choi; C A Moylan; C M Hunt Journal: Aliment Pharmacol Ther Date: 2017-11-08 Impact factor: 8.171